In adrenocortical carcinoma, the tumor can autonomously produce hormones at levels that cause clinically significant endocrine effects. When this hormone excess is clinically relevant, dedicated medical management is recommended in all affected patients alongside oncological care.
This protocol applies to adrenocortical carcinoma with clinically relevant autonomous hormone excess — where the tumor produces hormones independently of normal feedback regulation, leading to measurable and clinically important endocrine consequences that require active control.
Medical therapy targeted at controlling hormone excess is the central intervention — the specific pharmacological strategy depends on the type and severity of excess involved.
Goal: normalization of hormone levels, or improved well-being where direct normalization is not assessable.
DOI: 10.1530/EJE-18-0608